Since TZT activates both GIP and GLP-1, it induces a remarkable reduction in body weight, unlike GIPR agonist, which is implicated in the development of obesity when used alone (Seino and Yamazaki 2022). Here, GIPR is linked to obesity due to melanocortin 4 receptor deficiency.